Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria

Journal of Hypertension

Volumn 26, Issue 9, 2008, Pages 1849-1859

  Nishiyama, Akira ^a,b,c   Nakagawa, Toshitaka ^c   Kobori, Hiroyuki ^d   Nagai, Yukiko ^c   Okada, Noriyuki ^e   Konishi, Yoshio ^e   Morikawa, Takashi ^e   Okumura, Michiaki ^e   Meda, Isseiki ^e   Kiyomoto, Hideyasu ^b,c   Hosomi, Naohisa ^c   Mori, Takefumi ^f   Ito, Sadayoshi ^f   Imanishi, Masahito ^c  

^a Department of Pharmacology ^*  (Japan)

^b Hypertension and Kidney Disease Research Center   (Japan)

^c KAGAWA UNIVERSITY   (Japan)

^d TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e OSAKA CITY GENERAL HOSPITAL   (Japan)

^f TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Albuminuria; Angiotensin II; Otsuka Long Evans Tokushima Fatty rat; Telmisartan; Type 2 diabetes

Indexed keywords

ANGIOTENSIN II; DESMIN; GLUCOSE; HYDRALAZINE; TELMISARTAN; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MESSENGER RNA;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL GRANULE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; INTERSTITIAL NEPHRITIS; KIDNEY INJURY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PODOCYTE; POSTPRANDIAL STATE; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; ANIMAL; BLOOD PRESSURE; DIABETIC NEPHROPATHY; GENETICS; KIDNEY CORTEX; METABOLISM; PATHOLOGY; RENOVASCULAR HYPERTENSION;

ALBUMINURIA; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BENZIMIDAZOLES; BENZOATES; BLOOD GLUCOSE; BLOOD PRESSURE; COLLAGEN; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HYPERTENSION, RENAL; KIDNEY CORTEX; MALE; PODOCYTES; RATS; RATS, INBRED OLETF; RNA, MESSENGER;

EID: 58149216612     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283060efa     Document Type: Article

References (44)

1. Makino H, Nakamura Y, Wada J. Remission and regression of diabetic nephropathy. Hypertens Res 2003; 26:515-519.
2. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110:921 - 927.
3. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310:356-360.
4. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al., Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106:1777 -1782.
5. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in noninsulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997; 157:1413-2148.
6. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators: preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351:1941-1951.
7. Viberti G, Mogensen CE, Groop LC, Pauls JF, European Microalbuminuria Captopril Study Group. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 1994; 271:275-279.
8. Burnier M, Zanchi A. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 2006; 24:11 -25.
9. Viberti G, Wheeldon NM, MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106:672-678.
10. Sasso FC, Carbonara O, Persico M, Iafusco D, Salvatore T, D'Ambrosio R, et al. Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double- blind placebo-controlled crossover study. Diabetes Care 2002; 25:1909-1913.
11. Zandbergen AA, Baggen MG, Lamberts SW, Bootsma AH, de Zeeuw D, Ouwendijk RJ. Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. Arandomized clinical trial. Ann Intern Med 2003; 139:90-96.
12. Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, et al., INNOVATION Study Group. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007; 30:1577 -1578.
13. Nagai Y, Yao L, Kobori H, Miyata K, Ozawa Y, Miyatake A, et al. Temporary angiotensin II blockade at the prediabetic stage attenuates the development ofrenal injury in type 2 diabetic rats. J Am Soc Nephrol 2005; 16:703-711.
14. Yagi K, Kim S, Wanibuchi H, Yamashita T, Yamamura Y, Iwao H. Characteristics of diabetes, blood pressure, and cardiac and renal complications in Otsuka Long-Evans Tokushima Fatty rats. Hypertension 1997; 29:728-735.
15. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 1992; 41:1422 -1428.
16. Wienen W, Richard S, Champeroux P, Audeval-Gerard C. Comparative antihypertensive and renoprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats. JRenin Angiotensin Aldosterone Syst 2001; 2:31 -36.
17. Nishiyama A, Seth DM, Navar LG. Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension 2002; 39:129-134.
18. Kobori H, Ozawa Y, Suzaki Y, Nishiyama A. Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats. J Am Soc Nephrol 2005; 16:2073-2080.
19. Nagase M, Yoshida S, Shibata S, Nagase T, Gotoda T, Ando K, Fujita T. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol 2006; 17:3438-3446.
20. Ueno M, Dobrogowska DH, Vorbrodt AW. Immunocytochemical evaluation of the blood-brain barrier to endogenous albumin in the olfactory bulb and pons of senescence-accelerated mice (SAM). Histochem Cell Biol 1996; 105:203-212.
21. Kim JJ, Li JJ, Jung DS, Kwak SJ, Ryu DR, Yoo TH, et al. Differential expression of nephrin according to glomerular size in early diabetic kidney disease. J Am Soc Nephrol 2007; 18:2303-2310.
22. Sullivan JC, Semprun-Prieto L, Boesen EI, Pollock DM, Pollock JS. Sex and sex hormones influence the development of albuminuria and renal macrophage infiltration in spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol 2007; 293:R1573-R1579.
23. Nishiyama A, Yao L, Nagai Y, Miyata K, Yoshizumi M, Kagami S, et al. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 2004; 43:841 -848.
24. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. American Heart Association; American Diabetes Association: primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007; 115:114-126.
25. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
26. Japanese Society of Hypertension. Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). Hypertens Res 2006; 29(Suppl):S1-S105.
27. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
28. Yoo TH, Li JJ, Kim JJ, Jung DS, Kwak SJ, Ryu DR, et al. Activation of the renin-angiotensin system within podocytes in diabetes. Kidney Int 2007; 71:1019-1027.
29. Hoffmann S, Podlich D, Hahnel B, Kriz W, Gretz N. Angiotensin II type 1 receptor over expression in podocytes induces glomerulosclerosis in transgenic rats. J Am Soc Nephrol 2004; 15:1475-1487.
30. Suzuki K, Han GD, Miyauchi N, Hashimoto T, Nakatsue T, Fujioka Y, et al. Angiotensin II type 1 and type 2 receptors play opposite roles in regulating the barrier function of kidney glomerular capillary wall. Am J Pathol 2007; 170:1841 -1853.
31. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366:2026-2033.
32. Ogawa S, Takeuchi K, Mori T, Nako K, Tsubo Y, Ito S. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy. Hypertens Res 2007; 30:325-334.
33. Pollock CA, Poronnik P. Albumin transport and processing by the proximal tubule: physiology and pathophysiology. Curr Opin Nephrol Hypertens 2007; 16:359-364.
34. Tojo A, Onozato ML, Kurihara H, Sakai T, Goto A, Fujita T. Angiotensin II blockade restores albumin reabsorption in the proximal tubules of diabetic rats. Hypertens Res 2003; 26:413-419.
35. Navar LG, Nishiyama A. Why are angiotensin concentrations so high in the kidney? Curr Opin Nephrol Hypertens 2004; 13:107-115.
36. Nishiyama A, Seth DM, Navar LG. Renal interstitial fluid angiotensin I and angiotensin II concentrations during local angiotensin-converting enzyme inhibition. J Am Soc Nephrol 2002; 13:2207-2212.
37. Nishiyama A, Seth DM, Navar LG. Angiotensin II type 1 receptor-mediated augmentation of renal interstitial fluid angiotensin II in angiotensin II- induced hypertension. J Hypertens 2003; 21:1897-1903.
38. Nishiyama A, Yoshizumi M, Rahman M, Kobori H, Seth DM, Miyatake A, et al. Effects of AT1 receptor blockade on renal injury and mitogen- activated protein activity in Dahl salt-sensitive rats. Kidney Int 2004; 65:972-981.
39. Kobori H, Prieto-Carrasquero MC, Ozawa Y, Navar LG. AT1 receptor mediated augmentation of intrarenal angiotensinogen in angiotensin II- dependent hypertension. Hypertension 2004; 43:1126-1132.
40. Zhuo JL, Imig JD, Hammond TG, Orengo S, Benes E, Navar LG. Ang II accumulation in rat renal endosomes during Ang II-induced hypertension: role of AT(1) receptor. Hypertension 2002; 39:116-121.
41. Zhuo JL. Intracrine renin and angiotensin II: a novel role in cardiovascular and renal cellular regulation. J Hypertens 2006; 24:1017-1020.
42. Andrews PM. A scanning and transmission electron microscopic comparison of puromycin aminonucleoside-induced nephrosis to hyperalbuminemia-induced proteinuria with emphasis on kidney podocyte pedicel loss. Lab Invest 1977; 36:183-197.
43. Gross ML, Ritz E, Schoof A, Adamczak M, Koch A, Tulp O, et al. Comparison of renal morphology in the streptozotocin and the SHR/N-cp models of diabetes. Lab Invest 2004; 84:452-464.
44. Katsurada A, Hagiwara Y, Miyashita K, Satou R, Miyata K, Ohashi N, et al. Novel sandwich ELISA for human angiotensinogen. Am J Physiol Renal Physiol 2007; 293:F938-F945